More is not always better in hair growth factors. epidermal growth factor: hair growth factor involved in alopecia areata pathogenesis

El-Refai, Asmaa M; Elhabak, Doaa M; Khashaba, R.A.

doi:10.4103/ijt.ijt_51_20

Cited by 9 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EGF and/or TGF-, which are closely related to ErbB1, can suppress the formation of HF in the early phases of its growth [13]. EGF and EGFR shown the ability to limit hair shaft elongation and convert the morphology to a catagen growth pattern in human HF culture by inhibiting mitotic regulators such Rcc2 and Stathmin 1 [24].…”

Section: Discussionmentioning

confidence: 99%

Growth Factors and Microneedling in Alopecia Areata: A Narrative Review

Almutlq,

Bukhari

2024

Skin Appendage Disord

View full text Add to dashboard Cite

Alopecia areata (AA) is an autoimmune condition that causes non-scarring hair loss on the scalp or other hair-bearing surfaces. Various signalling molecules regulate the hair cycle and hair follicle regeneration. These include genes, growth factors, nuclear receptors, cytokines, and subcellular signalling pathways. Growth factors can cause the vascular endothelium and dermal fibroblasts to proliferate, extend the anagen phase, and delay the initiation of catagen in the hair follicle, thereby promoting hair growth. Microneedling causes the release of growth factors and has been shown to help high-molecular-weight drugs penetrate the stratum corneum and hair follicles. These recent discoveries regarding the pathogenesis of AA have resulted in the development of promising therapies. Herein, this article reviews the use of growth factors and microneedling in the treatment of AA and explores their efficacy and safety. Treatment with growth factors and microneedling appears to be highly effective for AA, with no major adverse effects, and may provide a new option for hair regeneration therapy. To support the efficacy of growth factors and microneedling for AA treatment, additional large-scale studies of patients with AA are needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Growth Factors and Microneedling in Alopecia Areata: A Narrative Review

Almutlq,

Bukhari

2024

Skin Appendage Disord

View full text Add to dashboard Cite

show abstract

“…Moreover, EGF has been shown to inhibit hair shaft elongation and change the morphology to catagen growth patterns by suppressing mitotic regulators including RCC2 and Statmin1 54,55 . El‐Refai et al also reported that EGF negatively impacts hair follicle growth and may be linked to the pathogenesis of alopecia areata 56 …”

Section: Hair Lossmentioning

confidence: 99%

“… 54 , 55 El‐Refai et al also reported that EGF negatively impacts hair follicle growth and may be linked to the pathogenesis of alopecia areata. 56 …”

Section: Hair Lossmentioning

confidence: 99%

The use of epidermal growth factor in dermatological practice

Shin

Koh

Lee

et al. 2022

International Wound Journal

View full text Add to dashboard Cite

Epidermal growth factor (EGF) is a growth factor that plays a pivotal role in wound healing and maintaining tissue homeostasis by regulating cell survival, proliferation, migration, and differentiation. Exogenous administration of bioidentical human recombinant epidermal growth factor (rhEGF) has been known to promote skin wound healing, although rhEGF is increasingly being used in drug delivery systems and nanotechnology. However, despite considerable attention being focused on the potential clinical applications of rhEGF in several dermatological conditions beyond wound healing, the number of studies still remains relatively low. Herein, we conducted a literature search of PubMed/Medline and Google Scholar databases to retrieve published literature related to rhEGF and summarised the effects of rhEGF in the treatment of various wound types, radiotherapy or chemotherapy‐related skin reactions, atopic dermatitis, skin aging, and post‐inflammatory hyperpigmentation.

show abstract

“…35 However, evidence on possible proalopecic action of growth factors is weak compared with the strong evidence of their substantial anti-alopecic effects. 36…”

mentioning

confidence: 99%

Efficacy of Adipocyte-Derived Stem Cells-Conditioned Media in Telogen Effluvium

Zari

2023

SCCAA

View full text Add to dashboard Cite

To assess the effectiveness of adipocyte-derived mesenchymal stem cells-conditioned media (ADSC-CM) formulation in telogen effluvium patients. Methods: A retrospective cohort study was conducted at a dermatology clinic in Jeddah, Saudi Arabia. The study included 50 consecutive patients aged 20-70 years, who were diagnosed with telogen effluvium. All patients received five monthly sessions of the same commercial ADSC-CM formulation, using a standardized application protocol. Pre-and post-intervention changes in trichometry parameters were analyzed. Results: There was a significant increase in mean hair density (up to 29.01 hair/cm 2 ; effect size 0.7-1.0), cumulative hair thickness (up to 2.67 units; effect size 0.7-1.4), and the number of follicular hair units (up to 19.96%; effect size 1.0-1.3) in all scalp regions (p < 0.001), associated with a decrease in mean trichometry-derived Sinclair scale by 0.8-1.3 (p < 0.001). Positive outcomes were observed in 70%-92% of the patients depending on the parameter and scalp region. There was no impact of the patient's age on ADSC-CM efficacy. Conclusion: ADSC-CM was successfully applied as a new treatment option for patients with telogen effluvium. These findings provide another therapeutic and research area for dermatologists to optimize the management of telogen effluvium and reduce its impact on patients.Plain Language Summary: Hair loss can be a distressing experience. Telogen effluvium, a common type of hair loss, was the focus of a study in Saudi Arabia. The goal? To see if a new treatment using a mixture of cytokines, growth factors, and proteins from fat cellderived stem cells (known as ADSC-CM) could help.The researchers worked with 50 people aged between 20 and 70, all of whom were experiencing telogen effluvium. The treatment involved five monthly sessions of the ADSC-CM product. The team measured aspects of hair growth before and after the treatment.What did they find? Encouraging signs! Hair density and thickness significantly improved across the scalp. Additionally, the severity of the hair loss condition was reduced. Between 70% and 92% of people saw positive changes depending on the area of the scalp and the specific measurement.The exciting part is that the age of the person did not affect how well the treatment worked. This suggests it could benefit a wide range of people.In a nutshell, this study suggests ADSC-CM may be a new and effective way to help people experiencing telogen effluvium. More research is needed, but it is a promising avenue for dermatologists to explore and could potentially help reduce the impact of hair loss on people's lives.

show abstract

More is not always better in hair growth factors. epidermal growth factor: hair growth factor involved in alopecia areata pathogenesis

Cited by 9 publications

References 20 publications

Growth Factors and Microneedling in Alopecia Areata: A Narrative Review

Growth Factors and Microneedling in Alopecia Areata: A Narrative Review

The use of epidermal growth factor in dermatological practice

Efficacy of Adipocyte-Derived Stem Cells-Conditioned Media in Telogen Effluvium

Contact Info

Product

Resources

About